Article Text
Abstract
In the tyrosine kinase inhibitor era, the blast phase of chronic myeloid leukaemia (BP-CML) renders an uncommon presentation and has a poor prognosis with an estimated overall survival below 20%. Mixed-phenotype blast phase is even more infrequent, presenting in 3.3% of these patients. Blast phase manifests along haematological sarcomas, with extramedullary activity in lymph nodes, skin and bone. We report the case of a patient with an ovarian sarcoma as an extramedullary presentation of mixed-phenotype BP-CML refractory to conventional treatment which responded to immunotherapy against CD33 and CD19.
- cancer - see oncology
- chronic myeloid leukaemia
- haematology (drugs and medicines)
- haematology (incl blood transfusion)
Statistics from Altmetric.com
Footnotes
Contributors RO-M, XC-R and PEB-I were responsible for the hemato-oncological treatment of the patient. LAWS was responsible for the surgical treatment of the patient. The original idea was conceived by RO-M. The text was written by PEB-I. The images were provided by LAWS. All authors contributed to the investigation and discussion of the case.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.